Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy

References

1. 1.↵
   2. Stupp R,
   3. Hegi ME,
   4. Mason WP, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Chinot OL

   . Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Expert Rev Anticancer Ther 2012;12:1413–27 doi:10.1586/era.12.128 pmid:23249106

   CrossRefPubMed
3. 3.↵
   2. Mukherji SK

   . Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010;31:235–36 doi:10.3174/ajnr.A1987 pmid:20037132

   Abstract/FREE Full Text
4. 4.↵
   2. Riina HA,
   3. Fraser JF,
   4. Fralin S, et al

   . Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009;8:145–50 pmid:20192120

   PubMed
5. 5.↵
   2. Boockvar JA,
   3. Tsiouris AJ,
   4. Hofstetter CP, et al

   . Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma: clinical article. J Neurosurg 2011;114:624–32 doi:10.3171/2010.9.JNS101223 pmid:20964595

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Burkhardt JK,
   3. Riina H,
   4. Shin BJ, et al

   . Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 2012;77:130–34 doi:10.1016/j.wneu.2011.05.056 pmid:22405392

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Jeon JY,
   3. Kovanlikaya I,
   4. Boockvar JA, et al

   . Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study. AJNR Am J Neuroradiol 2012;33:2095–102 doi:10.3174/ajnr.A3091 pmid:22576886

   Abstract/FREE Full Text
8. 8.↵
   2. Upadhyay N,
   3. Waldman AD

   . Conventional MRI evaluation of gliomas. Br J Radiol 2011;84(Spec No 2):S107–11 doi:10.1259/bjr/65711810 pmid:22433821

   Abstract/FREE Full Text
9. 9.↵
   2. Kickingereder P,
   3. Wiestler B,
   4. Burth S, et al

   . Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol 2015;17:1139–47 doi:10.1093/neuonc/nov028 pmid:25754089

   Abstract/FREE Full Text
10. 10.↵
    2. Schmainda KM,
    3. Zhang Z,
    4. Prah M, et al

    . Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015;17:1148–56 doi:10.1093/neuonc/nou364 pmid:25646027

    Abstract/FREE Full Text
11. 11.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
12. 12.↵
    2. Shin BJ,
    3. Burkhardt JK,
    4. Riina HA, et al

    . Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 2012;23:323–29, ix–x doi:10.1016/j.nec.2012.01.008 pmid:22440875

    CrossRefPubMed
13. 13.↵
    2. Boxerman JL,
    3. Schmainda KM,
    4. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    Abstract/FREE Full Text
14. 14.↵
    2. Paulson ES,
    3. Schmainda KM

    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13 doi:10.1148/radiol.2492071659 pmid:18780827

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Kalpathy-Cramer J,
    3. Gerstner ER,
    4. Emblem KE, et al

    . Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res 2014;74:4622–37 doi:10.1158/0008-5472.CAN-14-0383 pmid:25183787

    Abstract/FREE Full Text
16. 16.↵
    2. Huang RY,
    3. Neagu MR,
    4. Reardon DA, et al

    . Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy: detecting illusive disease, defining response. Front Neurol 2015;6:33 doi:10.3389/fneur.2015.00033 pmid:25755649

    CrossRefPubMed
17. 17.↵
    2. Falk AT,
    3. Barrière J,
    4. François E, et al

    . Bevacizumab: a dose review. Crit Rev Oncol Hematol 2015;94:311–22 doi:10.1016/j.critrevonc.2015.01.012 pmid:25703583

    CrossRefPubMed
18. 18.↵
    2. Jain RK,
    3. Duda DG,
    4. Clark JW, et al

    . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24–40 doi:10.1038/ncponc0403 pmid:16407877

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Okonogi N,
    3. Shirai K,
    4. Oike T, et al

    . Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme. Anticancer Res 2015;35:1229–35 pmid:25750269

    Abstract/FREE Full Text
20. 20.↵
    2. Essig M,
    3. Shiroishi MS,
    4. Nguyen TB, et al

    . Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24–34 doi:10.2214/AJR.12.9543 pmid:23255738

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Jahng GH,
    3. Li KL,
    4. Ostergaard L, et al

    . Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques. Korean J Radiol 2014;15:554–77 doi:10.3348/kjr.2014.15.5.554 pmid:25246817

    CrossRefPubMed
22. 22.↵
    2. Stadlbauer A,
    3. Pichler P,
    4. Karl M, et al

    . Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy. Eur J Radiol 2015;84:1128–36 doi:10.1016/j.ejrad.2015.02.025 pmid:25795194

    CrossRefPubMed
23. 23.↵
    2. de Groot JF,
    3. Fuller G,
    4. Kumar AJ, et al

    . Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233–42 doi:10.1093/neuonc/nop027 pmid:20167811

    Abstract/FREE Full Text
24. 24.↵
    2. Iwamoto FM,
    3. Abrey LE,
    4. Beal K, et al

    . Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200–06 doi:10.1212/WNL.0b013e3181bc0184 pmid:19822869

    Abstract/FREE Full Text
25. 25.↵
    2. Keunen O,
    3. Johansson M,
    4. Oudin A, et al

    . Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749–54 doi:10.1073/pnas.1014480108 pmid:21321221

    Abstract/FREE Full Text